XPH — SPDR® S&P® Pharmaceuticals ETF
Data updated: 2026-09-11
XPH — SPDR® S&P® Pharmaceuticals ETF. United States Small Cap Blend / Core Health Care Equity · $428.43M AUM. Holdings, fees, performance and SEC filings.
XPH Fund Overview
XPH — SPDR® S&P® Pharmaceuticals ETF is a US ETF managed by SPDR Series Trust, categorised as United States Small Cap Blend / Core Health Care Equity. ABC INVEST provides holdings, performance, costs, cashflows, risk data, prospectus documents and SEC filings, sourced from SEC filings.
- Type: US ETF
- Manager: SPDR Series Trust
- Category: United States Small Cap Blend / Core Health Care Equity
- Assets under management: $428.43M
- 1-year return: 64.9%
- Ticker: XPH
- SEC CIK: 0001064642
- SEC series ID: S000012321
- Share class ID: C000033537
XPH Holdings
Top 10 holdings of SPDR® S&P® Pharmaceuticals ETF by percentage of net assets, from the fund's latest SEC N-PORT filing.
| Holding | % of net assets |
|---|---|
| State Street Global Advisors | 8.64% |
| Definium Therapeutics Inc | 3.09% |
| MBX Biosciences Inc | 2.72% |
| Alumis Inc | 2.14% |
| AtaiBeckley Inc | 2.13% |
| Trevi Therapeutics Inc | 2.12% |
| Enliven Therapeutics Inc | 2.09% |
| Amylyx Pharmaceuticals Inc | 2.04% |
| VeraDermics Inc | 2.02% |
| Ligand Pharmaceuticals Inc | 1.94% |
XPH Portfolio Allocation
Asset-class allocation of SPDR® S&P® Pharmaceuticals ETF by percentage of net assets, from the latest SEC N-PORT filing.
| Asset class | Allocation |
|---|---|
| Equity | 99.9% |
| Cash & Equivalents | 8.6% |
XPH Performance
Total returns for XPH (as of 2026-09-01), from SEC filings.
| Period | Total return |
|---|---|
| YTD | 18.7% |
| 1 year | 64.9% |
| 3 years (annualised) | 18.8% |
| 5 years (annualised) | 6.5% |
XPH Risk Information
Risk metrics for XPH, derived from monthly returns in SEC filings.
- 1-year volatility (annualised): 21.2%
XPH Costs and Fees
XPH costs about $35 per $10,000 invested per year in fund expenses.
- Net expense ratio: 0.35%
- Gross expense ratio: 0.35%
- Portfolio turnover: 50%
- Brokerage commissions: 3.44 bps of average net assets (SEC N-CEN)
XPH Cashflows
Over the 12 months to 2026-06, SPDR® S&P® Pharmaceuticals ETF had net inflows of $159.80M, from monthly SEC N-PORT filings.
| Month | Net flow |
|---|---|
| 2026-06 | $27.03M |
| 2026-05 | −$5.42M |
| 2026-04 | $25.30M |
| 2026-03 | −$31.15K |
| 2026-02 | $28.22M |
| 2026-01 | $61.59M |
XPH Debt Constituents
No individual debt constituents are reported in SPDR® S&P® Pharmaceuticals ETF's latest SEC N-PORT filing.
XPH Prospectus and SEC Filings
Official SPDR® S&P® Pharmaceuticals ETF filings on SEC EDGAR — prospectus, portfolio holdings and annual reports.
- Prospectus (485BPOS) — filed 2025-10-24
- Prospectus (485BPOS) — filed 2024-10-24
- Prospectus (485BPOS) — filed 2023-10-26
- Portfolio holdings (N-PORT) — filed 2026-08-28
- Portfolio holdings (N-PORT) — filed 2026-05-28
- Portfolio holdings (N-PORT) — filed 2026-02-26
- Annual census (N-CEN) — filed 2026-09-11
- Annual census (N-CEN) — filed 2025-09-12
Related Funds
Other United States Small Cap Blend / Core Health Care Equity funds tracked on ABC INVEST:
Data Sources
ABC INVEST compiles this page from public filings made to the U.S. Securities and Exchange Commission (SEC) through EDGAR: portfolio holdings and monthly cashflows from Form N-PORT, expenses and returns from fund prospectuses (Form 485BPOS) and the SEC DERA Risk/Return Summary data sets, annual data from Form N-CEN, and shareholder reports from Form N-CSR.